Antihypertensive drug development: current challenges and future opportunities
- PMID: 20537610
- DOI: 10.1016/j.jash.2010.04.003
Antihypertensive drug development: current challenges and future opportunities
Abstract
The growing rate of obesity and diabetes, and an aging population has led to increased demand for new antihypertensive compounds. This review highlights the challenges and opportunities associated with each phase of drug discovery and development of novel antihypertensive agents. Discovery and development starts with identification of a protein hypothesized to be linked to hypertension. Using the information gathered during this early stage, several potential candidates are often synthesized and moved on through preclinical evaluations, eventually leading to selection of one or more compounds for testing in humans. The compounds then enter preclinical safety studies in laboratory animal species and subsequently are tested in tiered clinical studies. As the compounds enter clinical testing, there is an exponential increase in the investment of resources to demonstrate that a new compound is a viable and worthy therapeutic agent for hypertension. The review provides some forecasting of issues that are likely to impact drug development of novel antihypertensives in the future.
Copyright (c) 2010 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The future of antihypertensive treatment.Am J Ther. 2007 Mar-Apr;14(2):121-34. doi: 10.1097/01.pap.0000249915.12185.58. Am J Ther. 2007. PMID: 17414579 Review.
-
Alternative strategies in drug development: clinical pharmacological aspects.Int J Clin Pharmacol Ther. 1999 Dec;37(12):575-83. Int J Clin Pharmacol Ther. 1999. PMID: 10599949 Review.
-
Anticancer Drug Development: The Way Forward.Oncologist. 1996;1(3):180-181. Oncologist. 1996. PMID: 10387985
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Vet Pathol. 2009 Jan;46(1):10-24. doi: 10.1354/vp.46-1-10. Vet Pathol. 2009. PMID: 19112110 Review.
Cited by
-
Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.J Med Internet Res. 2016 Apr 1;18(4):e76. doi: 10.2196/jmir.4541. J Med Internet Res. 2016. PMID: 27036325 Free PMC article.
-
The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure.Pharmacol Ther. 2016 Aug;164:126-34. doi: 10.1016/j.pharmthera.2016.04.006. Epub 2016 Apr 23. Pharmacol Ther. 2016. PMID: 27113409 Free PMC article. Review.
-
Novel drugs targeting hypertension revisited.J Cardiovasc Pharmacol. 2010 Sep;56(3):213-4. doi: 10.1097/FJC.0b013e3181f0d63f. J Cardiovasc Pharmacol. 2010. PMID: 20844362 Free PMC article. No abstract available.
-
The physiological roles of phosducin: from retinal function to stress-dependent hypertension.Cell Mol Life Sci. 2011 Feb;68(4):599-612. doi: 10.1007/s00018-010-0550-0. Epub 2010 Oct 31. Cell Mol Life Sci. 2011. PMID: 21069424 Free PMC article. Review.
-
Iptakalim: A novel multi-utility potassium channel opener.J Pharmacol Pharmacother. 2012 Jan;3(1):12-4. doi: 10.4103/0976-500X.92495. J Pharmacol Pharmacother. 2012. PMID: 22368410 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials